vs
Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and Guardian Pharmacy Services, Inc. (GRDN). Click either name above to swap in a different company.
EDGEWELL PERSONAL CARE Co is the larger business by last-quarter revenue ($422.8M vs $397.6M, roughly 1.1× Guardian Pharmacy Services, Inc.). Guardian Pharmacy Services, Inc. runs the higher net margin — 5.3% vs -15.5%, a 20.8% gap on every dollar of revenue.
The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..
CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.
EPC vs GRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $422.8M | $397.6M |
| Net Profit | $-65.7M | $20.9M |
| Gross Margin | 38.1% | 21.5% |
| Operating Margin | -4.5% | 7.7% |
| Net Margin | -15.5% | 5.3% |
| Revenue YoY | -11.6% | — |
| Net Profit YoY | -3028.6% | — |
| EPS (diluted) | $-1.41 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $422.8M | $397.6M | ||
| Q3 25 | $600.5M | $377.4M | ||
| Q2 25 | $627.2M | $344.3M | ||
| Q1 25 | $580.7M | $329.3M | ||
| Q4 24 | $415.1M | — | ||
| Q3 24 | $517.6M | $314.4M | ||
| Q2 24 | $647.8M | — | ||
| Q1 24 | $599.4M | — |
| Q4 25 | $-65.7M | $20.9M | ||
| Q3 25 | $-30.6M | $9.8M | ||
| Q2 25 | $29.1M | $9.0M | ||
| Q1 25 | $29.0M | $9.4M | ||
| Q4 24 | $-2.1M | — | ||
| Q3 24 | $8.8M | $-122.0M | ||
| Q2 24 | $49.0M | — | ||
| Q1 24 | $36.0M | — |
| Q4 25 | 38.1% | 21.5% | ||
| Q3 25 | 37.9% | 19.8% | ||
| Q2 25 | 42.8% | 19.8% | ||
| Q1 25 | 44.1% | 19.5% | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | 19.4% | ||
| Q2 24 | 44.3% | — | ||
| Q1 24 | 43.1% | — |
| Q4 25 | -4.5% | 7.7% | ||
| Q3 25 | -4.2% | 4.3% | ||
| Q2 25 | 8.6% | 3.7% | ||
| Q1 25 | 10.1% | 3.9% | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 3.9% | -33.3% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | 11.7% | — |
| Q4 25 | -15.5% | 5.3% | ||
| Q3 25 | -5.1% | 2.6% | ||
| Q2 25 | 4.6% | 2.6% | ||
| Q1 25 | 5.0% | 2.9% | ||
| Q4 24 | -0.5% | — | ||
| Q3 24 | 1.7% | -38.8% | ||
| Q2 24 | 7.6% | — | ||
| Q1 24 | 6.0% | — |
| Q4 25 | $-1.41 | — | ||
| Q3 25 | $-0.65 | — | ||
| Q2 25 | $0.62 | — | ||
| Q1 25 | $0.60 | — | ||
| Q4 24 | $-0.04 | — | ||
| Q3 24 | $0.18 | — | ||
| Q2 24 | $0.98 | — | ||
| Q1 24 | $0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $65.6M |
| Total DebtLower is stronger | $1.5B | $0 |
| Stockholders' EquityBook value | $1.5B | $217.9M |
| Total Assets | $3.8B | $412.7M |
| Debt / EquityLower = less leverage | 1.03× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $65.6M | ||
| Q3 25 | — | $36.5M | ||
| Q2 25 | — | $18.8M | ||
| Q1 25 | — | $14.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $209.1M | $37.2M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.5B | $0 | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.3B | $34.3M | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $1.5B | $217.9M | ||
| Q3 25 | $1.6B | $195.5M | ||
| Q2 25 | $1.6B | $179.7M | ||
| Q1 25 | $1.5B | $163.2M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | $133.9M | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
| Q4 25 | $3.8B | $412.7M | ||
| Q3 25 | $3.8B | $390.0M | ||
| Q2 25 | $3.8B | $356.3M | ||
| Q1 25 | $3.8B | $334.0M | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.7B | $348.0M | ||
| Q2 24 | $3.7B | — | ||
| Q1 24 | $3.8B | — |
| Q4 25 | 1.03× | 0.00× | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 0.81× | 0.26× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-125.9M | $34.6M |
| Free Cash FlowOCF − Capex | $-137.5M | — |
| FCF MarginFCF / Revenue | -32.5% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | — | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $36.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-125.9M | $34.6M | ||
| Q3 25 | $74.1M | $28.2M | ||
| Q2 25 | $114.8M | $19.9M | ||
| Q1 25 | $45.1M | $17.6M | ||
| Q4 24 | $-115.6M | — | ||
| Q3 24 | $-388.3M | — | ||
| Q2 24 | $101.2M | — | ||
| Q1 24 | $129.0M | — |
| Q4 25 | $-137.5M | — | ||
| Q3 25 | $46.5M | $24.2M | ||
| Q2 25 | $99.3M | — | ||
| Q1 25 | $28.0M | — | ||
| Q4 24 | $-132.4M | — | ||
| Q3 24 | $-414.2M | — | ||
| Q2 24 | $88.6M | — | ||
| Q1 24 | $117.5M | — |
| Q4 25 | -32.5% | — | ||
| Q3 25 | 7.7% | 6.4% | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -31.9% | — | ||
| Q3 24 | -80.0% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 19.6% | — |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 4.6% | 1.1% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | 1.65× | ||
| Q3 25 | — | 2.87× | ||
| Q2 25 | 3.95× | 2.21× | ||
| Q1 25 | 1.56× | 1.86× | ||
| Q4 24 | — | — | ||
| Q3 24 | -44.13× | — | ||
| Q2 24 | 2.07× | — | ||
| Q1 24 | 3.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
GRDN
Segment breakdown not available.
